Elusys Therapeutics
Elusys Therapeutics is dedicated to delivering innovative medical countermeasures that enable fast, effective, and durable protection against infectious agents. Their mission is to accelerate the development and commercialization of novel biodefense solutions, such as their anthrax antitoxin ANTHIM®, for strategic government partners. They focus on developing antibody therapeutics for infectious diseases and have a strong partnership with government agencies to enhance biosecurity.
Industries
Nr. of Employees
small (1-50)
Patents
Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US-8093360-B2
View Details
Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US-8093360-B2
View DetailsProducts
Monoclonal antibody anthrax antitoxin (obiltoxaximab)
A monoclonal antibody antitoxin developed to neutralize anthrax toxin; indicated for treatment of inhalational anthrax in combination with antibacterial drugs and for post-exposure prophylaxis when alternatives are unavailable or inappropriate.
ANTHIM® (obiltoxaximab)
Anthrax antitoxin monoclonal antibody approved in the United States and Canada, stockpiled by the U.S. Strategic National Stockpile and the National Emergency Strategic Stockpile of Canada for biosecurity against anthrax attacks.
LAV-BASTA-48
Vaccine program for biological warfare pathogens and infectious disease threats targeting inhalational anthrax.
Monoclonal antibody anthrax antitoxin (obiltoxaximab)
A monoclonal antibody antitoxin developed to neutralize anthrax toxin; indicated for treatment of inhalational anthrax in combination with antibacterial drugs and for post-exposure prophylaxis when alternatives are unavailable or inappropriate.
ANTHIM® (obiltoxaximab)
Anthrax antitoxin monoclonal antibody approved in the United States and Canada, stockpiled by the U.S. Strategic National Stockpile and the National Emergency Strategic Stockpile of Canada for biosecurity against anthrax attacks.
LAV-BASTA-48
Vaccine program for biological warfare pathogens and infectious disease threats targeting inhalational anthrax.
Services
Advisory services covering program strategy, regulatory pathway planning, and government contract navigation for organizations developing medical countermeasures.
Consulting support for manufacturing scale-up, process validation, and implementation of quality management systems for biologic therapeutics.
Advisory services covering program strategy, regulatory pathway planning, and government contract navigation for organizations developing medical countermeasures.
Consulting support for manufacturing scale-up, process validation, and implementation of quality management systems for biologic therapeutics.
Expertise Areas
- Monoclonal antibody therapeutics
- Biodefense medical countermeasures
- Clinical trial design and execution for infectious diseases
- Preclinical animal efficacy models
Key Technologies
- Monoclonal antibody production
- Intravenous single-dose formulation
- Lyophilized formulation development
- Preclinical infectious-disease challenge models
News & Updates
Elusys finalized a contract with the Canadian government to deliver ANTHIM® for use against a potential anthrax attack, marking the first international sale of ANTHIM®.
Elusys Finalizes HHS Contract to Deliver ANTHIM® to the U.S. Department of Health and Human Services
Elusys announced the finalization of a contract to deliver ANTHIM® to the US HHS.
Received market clearance by the U.S. Food and Drug Administration in March 2016 for the treatment and prevention of inhalational anthrax.
Elusys finalized a contract with the Canadian government to deliver ANTHIM® for use against a potential anthrax attack, marking the first international sale of ANTHIM®.
Elusys Finalizes HHS Contract to Deliver ANTHIM® to the U.S. Department of Health and Human Services
Elusys announced the finalization of a contract to deliver ANTHIM® to the US HHS.
Received market clearance by the U.S. Food and Drug Administration in March 2016 for the treatment and prevention of inhalational anthrax.